MX2010007501A - Conjugados de n-alcoxiamida como agentes formadores de imagen. - Google Patents

Conjugados de n-alcoxiamida como agentes formadores de imagen.

Info

Publication number
MX2010007501A
MX2010007501A MX2010007501A MX2010007501A MX2010007501A MX 2010007501 A MX2010007501 A MX 2010007501A MX 2010007501 A MX2010007501 A MX 2010007501A MX 2010007501 A MX2010007501 A MX 2010007501A MX 2010007501 A MX2010007501 A MX 2010007501A
Authority
MX
Mexico
Prior art keywords
plaque
arterial
imaging
methods
detecting
Prior art date
Application number
MX2010007501A
Other languages
English (en)
Spanish (es)
Inventor
Thomas D Harris
Padmaja Yalamanchili
David S Casebier
Richard R Cesati
Simon P Robinson
Richard J Looby
Edward H Cheesman
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Publication of MX2010007501A publication Critical patent/MX2010007501A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2010007501A 2008-01-08 2009-01-08 Conjugados de n-alcoxiamida como agentes formadores de imagen. MX2010007501A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1962708P 2008-01-08 2008-01-08
PCT/US2009/000096 WO2009089022A1 (en) 2008-01-08 2009-01-08 N-alkoxyamide conjugates as imaging agents

Publications (1)

Publication Number Publication Date
MX2010007501A true MX2010007501A (es) 2010-08-16

Family

ID=40456854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007501A MX2010007501A (es) 2008-01-08 2009-01-08 Conjugados de n-alcoxiamida como agentes formadores de imagen.

Country Status (14)

Country Link
US (4) US8361438B2 (enExample)
EP (1) EP2240206B1 (enExample)
JP (2) JP5730581B2 (enExample)
KR (2) KR101861025B1 (enExample)
CN (2) CN103965128B (enExample)
AU (2) AU2009204427B2 (enExample)
BR (1) BRPI0907612A2 (enExample)
CA (1) CA2711426C (enExample)
ES (1) ES2629340T3 (enExample)
IL (1) IL206846A (enExample)
MX (1) MX2010007501A (enExample)
TW (1) TWI465251B (enExample)
WO (1) WO2009089022A1 (enExample)
ZA (1) ZA201005130B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3209821B2 (ja) 1993-03-31 2001-09-17 日立ビアメカニクス株式会社 消耗電極式ガスシールドアーク溶接の出力制御方法およびその溶接装置
KR101861025B1 (ko) 2008-01-08 2018-05-24 랜티우스 메디컬 이메징, 인크. 영상화 제제로서의 ｎ-알콕시아미드 접합체
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
DK3929196T3 (da) 2013-09-24 2023-09-25 Fujifilm Corp Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5122885A (en) * 1974-08-13 1976-02-23 Sagami Chem Res Ashiru ll aminosan oo chikanhidorokisamidono seizohoho
JPS5910322B2 (ja) 1975-07-30 1984-03-08 三井東圧化学株式会社 殺草剤
HU175152B (hu) * 1976-12-30 1980-05-28 Richter Gedeon Vegyeszet Sposob poluchenija peptidov s gastrin-aktivnost'ju, soderzhahhikh amino-oksi-kisloty
US4859777A (en) 1981-07-01 1989-08-22 Eastman Kodak Company Terpyridine chelating agents
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
AU6621586A (en) 1985-11-18 1987-06-02 University Of Texas System, The Polychelating agents for image and spectral enhancement (and spectral shift)
DE3768523D1 (de) 1986-02-18 1991-04-18 Squibb & Sons Inc ((2,2,2-trichloroethoxy)methoxy)amin.
US5064956A (en) 1987-06-24 1991-11-12 The Dow Chemical Company Process for preparing mono-n-alkylated polyazamacrocycles
JP2573006B2 (ja) 1987-12-17 1997-01-16 富士薬品工業株式会社 新規なヒドロキサム酸誘導体
IT1224627B (it) 1988-04-12 1990-10-04 Guidotti & C Spa Labor Ammidi di acidi ciclometilen_1,2_dicarbossilici adattivita' terapeutica, procedimenti per la loro preparazione e composizioni farmaceutiche che le contengono.
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5089043A (en) 1989-11-09 1992-02-18 Shionogi & Co., Ltd. Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides
JPH0491070A (ja) * 1990-08-06 1992-03-24 Kanebo Ltd カリックスアレーン誘導体
US5274129A (en) * 1991-06-12 1993-12-28 Idaho Research Foundation, Inc. Hydroxamic acid crown ethers
US5225173A (en) * 1991-06-12 1993-07-06 Idaho Research Foundation, Inc. Methods and devices for the separation of radioactive rare earth metal isotopes from their alkaline earth metal precursors
GB9115375D0 (en) * 1991-07-17 1991-09-04 Salutar Inc Compounds
US5639746A (en) 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
TW319763B (enExample) 1995-02-01 1997-11-11 Epix Medical Inc
EP0955044B1 (en) * 1995-06-26 2005-11-16 Chelator LLC Method of inhibiting bacterial or fungal growth using a complexing agent
EP0850215B1 (en) * 1995-07-26 2000-10-18 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US6461587B1 (en) * 1999-03-22 2002-10-08 Schering Aktiengesellschaft Perfluoroalkylamides, their production and their use in diagnosis
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
EP1377321A4 (en) 2001-02-23 2006-01-11 Bristol Myers Squibb Co RECOVERY ANTAGONISTS RECEIVING DETECTABLE MACROPHAGE RECEPTORS FOR THE IDENTIFICATION OF ATHEROSCLEROSIS AND VULNERABLE PLAQUE BY IMAGING
JP4590157B2 (ja) * 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
CA2526760A1 (en) * 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
WO2004112840A2 (en) 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
JP4912153B2 (ja) 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
US20070142417A1 (en) * 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
CA2613439A1 (en) 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
DE102005033902B3 (de) * 2005-07-15 2007-04-05 Schering Ag Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel
US7618957B2 (en) 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
KR101861025B1 (ko) * 2008-01-08 2018-05-24 랜티우스 메디컬 이메징, 인크. 영상화 제제로서의 ｎ-알콕시아미드 접합체
WO2011000532A2 (de) 2009-07-03 2011-01-06 Archimica Gmbh Verfahren zur enantioselektiven addition von organometallischen kohlenstoffnukleophilen an trifluormethylketone und verwendung des verfahrens in der synthese von hiv reverse transcriptase inhibitoren
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents

Also Published As

Publication number Publication date
KR20160022394A (ko) 2016-02-29
AU2014200012C1 (en) 2016-12-15
JP5730581B2 (ja) 2015-06-10
EP2240206A1 (en) 2010-10-20
KR101595324B1 (ko) 2016-02-18
CA2711426C (en) 2018-05-22
US9266846B2 (en) 2016-02-23
AU2009204427B2 (en) 2013-10-03
JP6087386B2 (ja) 2017-03-01
CN103965128B (zh) 2018-04-03
JP2015180623A (ja) 2015-10-15
ES2629340T3 (es) 2017-08-08
IL206846A (en) 2015-05-31
US20130315822A1 (en) 2013-11-28
CN101970015A (zh) 2011-02-09
US20150094465A1 (en) 2015-04-02
CN103965128A (zh) 2014-08-06
US20160185737A1 (en) 2016-06-30
EP2240206B1 (en) 2017-03-22
KR101861025B1 (ko) 2018-05-24
ZA201005130B (en) 2014-12-23
US8361438B2 (en) 2013-01-29
US20090252676A1 (en) 2009-10-08
WO2009089022A1 (en) 2009-07-16
US20170029386A9 (en) 2017-02-02
IL206846A0 (en) 2010-12-30
US8852553B2 (en) 2014-10-07
TW200936169A (en) 2009-09-01
CN101970015B (zh) 2014-05-07
HK1200823A1 (en) 2015-08-14
AU2009204427A1 (en) 2009-07-16
CA2711426A1 (en) 2009-07-16
AU2014200012B2 (en) 2016-06-23
TWI465251B (zh) 2014-12-21
US9732047B2 (en) 2017-08-15
JP2011509294A (ja) 2011-03-24
KR20100103672A (ko) 2010-09-27
BRPI0907612A2 (pt) 2015-07-21

Similar Documents

Publication Publication Date Title
WO2011005322A3 (en) N-alkoxyamide conjugates as imaging agents
WO2010091049A3 (en) Diagnosis and treatment of cancer
EP2496720A4 (en) NON-INVASIVE DIAGNOSIS OF GRAFT REJECTION IN PATIENTS WITH ORGAN TRANSPLANT
WO2010129494A3 (en) Method and apparatus for quantitative imaging of blood perfusion in living tissue
WO2008005535A3 (en) Expandable vascular endoluminal prostheses
FR2928019B1 (fr) Mesures clairsemees de proprietes du tissu dans l'imagerie medicale par ultrason
WO2009099955A3 (en) Vascular access to extra-vascular space
MX2010002543A (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2010144678A3 (en) Generation of vascularized human heart tissue and uses thereof
WO2009057165A8 (en) Use of microvesicles (mvs) derived from stem cells for preparing a medicament for endo/epithelial regeneration of damaged or injured tissues or organs, and related in vitro and in vivo methods
EP2182840A4 (en) NON-INVASIVE CHARACTERIZATION OF HUMAN VESSELS
EP2103312A4 (en) PREPARATION FOR STERILIZATION OR DISINFECTION OF TISSUE
NO20076423L (no) Hydrazidkonjugater som billeddannende midler
EP2318834A4 (en) USE OF BACTERIAL BETA LACTAMASE FOR IN VITRO DIAGNOSTICS AND IN VIVO IMAGING, DIAGNOSTICS AND THERAPEUTICS
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
WO2012048170A3 (en) Humanized animals via tissue engineering and uses therefor
ATE460940T1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
EP1960052A4 (en) TREATMENT OF LESIONS OR IMPERFECTIONS OF SKIN MAMMALIAN TISSUES OR CLOSE TO THE SKIN OR IN OR NEAR OTHER ANATOMIC SURFACES
EP1766079A4 (en) DIAGNOSIS OR PREDICTION OF THE DEADLINE OF BREAST CANCER
EP2421554A4 (en) TISSUE KALLICREIN FOR THE TREATMENT OF HUNTINGTON'S DISEASE
Berardinelli et al. Malignancies in 2753 kidney recipients transplanted during a 39-year experience
WO2008009655A3 (de) Medizinische verwendung von n-phenylpropenoyl-aminosäurederivaten und verwandten verbindungen
ATE320272T1 (de) Verwendung von kontrastmitteln zur herstellung eines diagnostischen mittels für die darm- lumenbildgebung
Yeung et al. Multifocal lymphangioendotheliomatosis with thrombocytopenia

Legal Events

Date Code Title Description
FG Grant or registration